Report Thumbnail
Product Code LP0913410471V0H
Published Date 2023/2/9
LP Information
English101 PagesGlobal

Global Hemophilia Drugs Market Growth 2023-2029 ‐ Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0913410471V0H◆The Feb 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/2/9
LP Information
English 101 PagesGlobal

Global Hemophilia Drugs Market Growth 2023-2029 ‐ Pharmaceutical_LifeSciense Market


Abstract

Summary

The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab’ by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate’ for type A and ‘Aprolix’ for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.
LPI (LP Information)' newest research report, the “Hemophilia Drugs Industry Forecast” looks at past sales and reviews total world Hemophilia Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Hemophilia Drugs sales for 2023 through 2029. With Hemophilia Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hemophilia Drugs industry.
This Insight Report provides a comprehensive analysis of the global Hemophilia Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hemophilia Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Hemophilia Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hemophilia Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hemophilia Drugs.
The global Hemophilia Drugs market size is projected to grow from US$ 12460 million in 2022 to US$ 16680 million in 2029; it is expected to grow at a CAGR of 16680 from 2023 to 2029.
With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth over the forecast period.
This report presents a comprehensive overview, market shares, and growth opportunities of Hemophilia Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Hemophilia A
Inhibitors
Hemophilia B
Von Willebrand Disease
Segmentation by application
Recombinant Therapies
Plasma-Derived Therapies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Baxalta
Bayer
CSL Behring
Pfizer
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F. Hoffmann-La Roche
Grifols
Octapharma
Sangamo Biosciences
Spark Therapeutics
Swedish Orphan Biovitrum
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hemophilia Drugs market?
What factors are driving Hemophilia Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hemophilia Drugs market opportunities vary by end market size?
How does Hemophilia Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats

  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Hemophilia Drugs Annual Sales 2018-2029
      • 2.1.2 World Current & Future Analysis for Hemophilia Drugs by Geographic Region, 2018, 2022 & 2029
      • 2.1.3 World Current & Future Analysis for Hemophilia Drugs by Country/Region, 2018, 2022 & 2029
    • 2.2 Hemophilia Drugs Segment by Type
      • 2.2.1 Hemophilia A
      • 2.2.2 Inhibitors
      • 2.2.3 Hemophilia B
      • 2.2.4 Von Willebrand Disease
    • 2.3 Hemophilia Drugs Sales by Type
      • 2.3.1 Global Hemophilia Drugs Sales Market Share by Type (2018-2023)
      • 2.3.2 Global Hemophilia Drugs Revenue and Market Share by Type (2018-2023)
      • 2.3.3 Global Hemophilia Drugs Sale Price by Type (2018-2023)
    • 2.4 Hemophilia Drugs Segment by Application
      • 2.4.1 Recombinant Therapies
      • 2.4.2 Plasma-Derived Therapies
    • 2.5 Hemophilia Drugs Sales by Application
      • 2.5.1 Global Hemophilia Drugs Sale Market Share by Application (2018-2023)
      • 2.5.2 Global Hemophilia Drugs Revenue and Market Share by Application (2018-2023)
      • 2.5.3 Global Hemophilia Drugs Sale Price by Application (2018-2023)

  • 3 Global Hemophilia Drugs by Company

    • 3.1 Global Hemophilia Drugs Breakdown Data by Company
      • 3.1.1 Global Hemophilia Drugs Annual Sales by Company (2018-2023)
      • 3.1.2 Global Hemophilia Drugs Sales Market Share by Company (2018-2023)
    • 3.2 Global Hemophilia Drugs Annual Revenue by Company (2018-2023)
      • 3.2.1 Global Hemophilia Drugs Revenue by Company (2018-2023)
      • 3.2.2 Global Hemophilia Drugs Revenue Market Share by Company (2018-2023)
    • 3.3 Global Hemophilia Drugs Sale Price by Company
    • 3.4 Key Manufacturers Hemophilia Drugs Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Hemophilia Drugs Product Location Distribution
      • 3.4.2 Players Hemophilia Drugs Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion

  • 4 World Historic Review for Hemophilia Drugs by Geographic Region

    • 4.1 World Historic Hemophilia Drugs Market Size by Geographic Region (2018-2023)
      • 4.1.1 Global Hemophilia Drugs Annual Sales by Geographic Region (2018-2023)
      • 4.1.2 Global Hemophilia Drugs Annual Revenue by Geographic Region (2018-2023)
    • 4.2 World Historic Hemophilia Drugs Market Size by Country/Region (2018-2023)
      • 4.2.1 Global Hemophilia Drugs Annual Sales by Country/Region (2018-2023)
      • 4.2.2 Global Hemophilia Drugs Annual Revenue by Country/Region (2018-2023)
    • 4.3 Americas Hemophilia Drugs Sales Growth
    • 4.4 APAC Hemophilia Drugs Sales Growth
    • 4.5 Europe Hemophilia Drugs Sales Growth
    • 4.6 Middle East & Africa Hemophilia Drugs Sales Growth

  • 5 Americas

    • 5.1 Americas Hemophilia Drugs Sales by Country
      • 5.1.1 Americas Hemophilia Drugs Sales by Country (2018-2023)
      • 5.1.2 Americas Hemophilia Drugs Revenue by Country (2018-2023)
    • 5.2 Americas Hemophilia Drugs Sales by Type
    • 5.3 Americas Hemophilia Drugs Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil

  • 6 APAC

    • 6.1 APAC Hemophilia Drugs Sales by Region
      • 6.1.1 APAC Hemophilia Drugs Sales by Region (2018-2023)
      • 6.1.2 APAC Hemophilia Drugs Revenue by Region (2018-2023)
    • 6.2 APAC Hemophilia Drugs Sales by Type
    • 6.3 APAC Hemophilia Drugs Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan

  • 7 Europe

    • 7.1 Europe Hemophilia Drugs by Country
      • 7.1.1 Europe Hemophilia Drugs Sales by Country (2018-2023)
      • 7.1.2 Europe Hemophilia Drugs Revenue by Country (2018-2023)
    • 7.2 Europe Hemophilia Drugs Sales by Type
    • 7.3 Europe Hemophilia Drugs Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia

  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Hemophilia Drugs by Country
      • 8.1.1 Middle East & Africa Hemophilia Drugs Sales by Country (2018-2023)
      • 8.1.2 Middle East & Africa Hemophilia Drugs Revenue by Country (2018-2023)
    • 8.2 Middle East & Africa Hemophilia Drugs Sales by Type
    • 8.3 Middle East & Africa Hemophilia Drugs Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries

  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends

  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Hemophilia Drugs
    • 10.3 Manufacturing Process Analysis of Hemophilia Drugs
    • 10.4 Industry Chain Structure of Hemophilia Drugs

  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Hemophilia Drugs Distributors
    • 11.3 Hemophilia Drugs Customer

  • 12 World Forecast Review for Hemophilia Drugs by Geographic Region

    • 12.1 Global Hemophilia Drugs Market Size Forecast by Region
      • 12.1.1 Global Hemophilia Drugs Forecast by Region (2024-2029)
      • 12.1.2 Global Hemophilia Drugs Annual Revenue Forecast by Region (2024-2029)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Hemophilia Drugs Forecast by Type
    • 12.7 Global Hemophilia Drugs Forecast by Application

  • 13 Key Players Analysis

    • 13.1 Baxalta
      • 13.1.1 Baxalta Company Information
      • 13.1.2 Baxalta Hemophilia Drugs Product Portfolios and Specifications
      • 13.1.3 Baxalta Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.1.4 Baxalta Main Business Overview
      • 13.1.5 Baxalta Latest Developments
    • 13.2 Bayer
      • 13.2.1 Bayer Company Information
      • 13.2.2 Bayer Hemophilia Drugs Product Portfolios and Specifications
      • 13.2.3 Bayer Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.2.4 Bayer Main Business Overview
      • 13.2.5 Bayer Latest Developments
    • 13.3 CSL Behring
      • 13.3.1 CSL Behring Company Information
      • 13.3.2 CSL Behring Hemophilia Drugs Product Portfolios and Specifications
      • 13.3.3 CSL Behring Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.3.4 CSL Behring Main Business Overview
      • 13.3.5 CSL Behring Latest Developments
    • 13.4 Pfizer
      • 13.4.1 Pfizer Company Information
      • 13.4.2 Pfizer Hemophilia Drugs Product Portfolios and Specifications
      • 13.4.3 Pfizer Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.4.4 Pfizer Main Business Overview
      • 13.4.5 Pfizer Latest Developments
    • 13.5 Alnylam Pharmaceuticals
      • 13.5.1 Alnylam Pharmaceuticals Company Information
      • 13.5.2 Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolios and Specifications
      • 13.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.5.4 Alnylam Pharmaceuticals Main Business Overview
      • 13.5.5 Alnylam Pharmaceuticals Latest Developments
    • 13.6 BioMarin
      • 13.6.1 BioMarin Company Information
      • 13.6.2 BioMarin Hemophilia Drugs Product Portfolios and Specifications
      • 13.6.3 BioMarin Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.6.4 BioMarin Main Business Overview
      • 13.6.5 BioMarin Latest Developments
    • 13.7 Catalyst Biosciences
      • 13.7.1 Catalyst Biosciences Company Information
      • 13.7.2 Catalyst Biosciences Hemophilia Drugs Product Portfolios and Specifications
      • 13.7.3 Catalyst Biosciences Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.7.4 Catalyst Biosciences Main Business Overview
      • 13.7.5 Catalyst Biosciences Latest Developments
    • 13.8 Dimension Therapeutics
      • 13.8.1 Dimension Therapeutics Company Information
      • 13.8.2 Dimension Therapeutics Hemophilia Drugs Product Portfolios and Specifications
      • 13.8.3 Dimension Therapeutics Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.8.4 Dimension Therapeutics Main Business Overview
      • 13.8.5 Dimension Therapeutics Latest Developments
    • 13.9 F. Hoffmann-La Roche
      • 13.9.1 F. Hoffmann-La Roche Company Information
      • 13.9.2 F. Hoffmann-La Roche Hemophilia Drugs Product Portfolios and Specifications
      • 13.9.3 F. Hoffmann-La Roche Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.9.4 F. Hoffmann-La Roche Main Business Overview
      • 13.9.5 F. Hoffmann-La Roche Latest Developments
    • 13.10 Grifols
      • 13.10.1 Grifols Company Information
      • 13.10.2 Grifols Hemophilia Drugs Product Portfolios and Specifications
      • 13.10.3 Grifols Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.10.4 Grifols Main Business Overview
      • 13.10.5 Grifols Latest Developments
    • 13.11 Octapharma
      • 13.11.1 Octapharma Company Information
      • 13.11.2 Octapharma Hemophilia Drugs Product Portfolios and Specifications
      • 13.11.3 Octapharma Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.11.4 Octapharma Main Business Overview
      • 13.11.5 Octapharma Latest Developments
    • 13.12 Sangamo Biosciences
      • 13.12.1 Sangamo Biosciences Company Information
      • 13.12.2 Sangamo Biosciences Hemophilia Drugs Product Portfolios and Specifications
      • 13.12.3 Sangamo Biosciences Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.12.4 Sangamo Biosciences Main Business Overview
      • 13.12.5 Sangamo Biosciences Latest Developments
    • 13.13 Spark Therapeutics
      • 13.13.1 Spark Therapeutics Company Information
      • 13.13.2 Spark Therapeutics Hemophilia Drugs Product Portfolios and Specifications
      • 13.13.3 Spark Therapeutics Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.13.4 Spark Therapeutics Main Business Overview
      • 13.13.5 Spark Therapeutics Latest Developments
    • 13.14 Swedish Orphan Biovitrum
      • 13.14.1 Swedish Orphan Biovitrum Company Information
      • 13.14.2 Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolios and Specifications
      • 13.14.3 Swedish Orphan Biovitrum Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.14.4 Swedish Orphan Biovitrum Main Business Overview
      • 13.14.5 Swedish Orphan Biovitrum Latest Developments

  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.